• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Michigan issues restricted formulary

Article

Lansing, Mich. - In a move to reduce drug expenditures for someMedicaid patients, Michigan has published a restricted formulary involving40 categories of illness, including two dermatology classes.

Related Videos
Related Content
Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma

Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma

Article
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

Podcast
New Dermatology Social Comparison Scale Demonstrates Acceptable Psychometrics for Clinical and Research Applications

New Dermatology Social Comparison Scale Demonstrates Acceptable Psychometrics for Clinical and Research Applications

Article
ReV Up Your Vitiligo Treatment Strategies

ReV Up Your Vitiligo Treatment Strategies

Podcast
A Novel Approach to Distinguishing Scabies From Atopic Dermatitis

A Novel Approach to Distinguishing Scabies From Atopic Dermatitis

Article
Secukinumab Demonstrates Promise for Patients With Severe Hidradenitis Suppurativa Who Found Adalimumab Intolerable

Secukinumab Demonstrates Promise for Patients With Severe Hidradenitis Suppurativa Who Found Adalimumab Intolerable

Article
© 2024 MJH Life Sciences

All rights reserved.